Prominent publications by Elli Trolle
ABNORMALITIES IN LIVER FUNCTION TESTS DURING LONG‐TERM DIPHENYLHYDANTOIN THERAPY IN EPILEPTIC OUT‐PATIENTS
[ PUBLICATION ]
Abstract. Fifty-one epileptic out-patients on long-term anticonvulsant treatment with diphenylhydantoin (DPH) alone or a combined regimen have been investigated and compared with a group of 250 control patients. The epileptics had significantly raised serum alkaline phosphatases, serum alanine aminotransferase, and plasma prothrombin time. Serum albumin was significantly decreased, as well as serum calcium and serum bilirubin. In male epileptics significantly raised serum phosphate ...
|Also Ranks for: Liver Function Tests | anticonvulsant drugs | epilepsy female humans | transaminase alkaline | serum bilirubin|
175 Epileptics were treated with Zarontin during a period from 6 months to 3 years. Zarontin is a powerful agent in the treatment of minor attacks, especially petit mal in childhood, but even myoclonic seizures and uncharacteristic small fits in adulthood may respond well to Zarontin.
Zarontin is usually tolerated well, but serious blood damage may appear and the possibility must always be kept in mind. In our series one patient during treatment developed a serious pancytopenia.
|Also Ranks for: Absence Epilepsy | 6 months | ethosuximide treatment | drug therapy | tonic clonic|
Treatment of Petit Mal Epilepsy with the New Succinimides: PM 680 and Celontin: (A Clinical Comparative Study)
[ PUBLICATION ]
The newer succinimides PM 680 and celontin have shown a satisfactory effect on petit mal epilepsy. More than 50% of the patients became seizure-free or practically seizure-free, and both drugs appeared definitely superior to milontin and oxazolidine compounds. PM 680 was much less toxic than celontin and should be preferred to celontin if available. At the moment PM 680 is not on the market.
No serious toxic reactions which could be considered with certainty to be caused by the drugs ...
|Also Ranks for: Petit Epilepsy | ont été | patients seizure|
Elli Trolle: Influence Statistics
|pouvant être considéré||#1|
|sévère contrôle clinique||#1|
|peut survenir graves||#1|
|intensive clinical control||#1|
|celontin treatment drugs||#1|
|uncharacteristic small fits||#1|
|être administrés sévère||#1|
|regular clinical control||#1|
|680 célontine ont||#1|
|zarontin ethosuximide zarontin||#1|
|dune absence epilepsy||#1|
|tout particulièrement relevée||#1|
|absence succinimides celontin||#1|
|powerful agent treatment||#1|
|réagir bien toléré||#1|
|175 epileptics zarontin||#1|
|ainsi dire délivrés||#1|
|minor attacks petit||#1|
Key People For Liver Function Tests
Elli Trolle:Expert Impact
Concepts for whichElli Trollehas direct influence:Liver function tests, Clonazepam patients, Clinical comparative study, Visual agnosia, Absence epilepsy, Petit epilepsy, Patients clonazepam, New succinimides.
Elli Trolle:KOL impact
Concepts related to the work of other authors for whichfor which Elli Trolle has influence:Electroconvulsive therapy, Clonazepam patients, Gingival hyperplasia, Visual imagery, Absence epilepsy, Alkaline phosphatase, Liver function tests.
Is this your profile? Claim your profile Copy URL Embed Link to your profile